1,744,172 research outputs found
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-5
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p>apamycin and early CCI-779-treated cohorts. c) Data shown in table format
Identification and regionalization of dominant runoff processes – a GIS-based and a statistical approach
No full textIn this study two approaches are presented to identify Dominant Runoff Processes (DRP) with respect to regionalization. The approaches are a simplification of an existing method to determine DRP by means of an extensive field campaign. The first approach combines the permeability of the substratum, land-use and slope of the basin in a GIS-based analysis. The second approach makes use of discriminant analysis of the physiographic characteristics of the basin and links it to the GIS analysis. The results of the developed approaches are maps, which identify dominant runoff processes and represent a spatial distribution of the hydrological behaviour of the soil during prolonged rainfall events. The approaches have been developed in a micro-scale basin (Germany). An additional meso-scale basin was introduced in which the two approaches were applied for quality control. The thus generated maps for the micro-scale basin were compared with an existing DRP map, which was derived with the existing method. The first approach showed a resemblance of 79% when compared to this map, whereas the second approach showed only a resemblance of 51%. The generated maps for the meso-scale basin were compared to DRP that were determined point wise according to the existing method. The first approach showed in this case a resemblance of 81%, whereas the second approach showed a resemblance of 68%. Therefore, the first approach is preferred to the second approach when accuracy, data input and calculation time are concerned.WatermanagementCivil Engineering and Geoscience
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-2
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p>graphical format. b) Average total score per kidney and average score per kidney for each lesion subtype by cohort in table format. "Both" refers to a combination of CCI-779 and IFN-γ
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-1
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-6
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p>t was administered. Whole blood, brain, kidney, and tumor tissue were collected at necropsy. a) Blood, brain, and kidney rapamycin levels from cohorts treated with rapamycin or CCI-779 for four consecutive days and euthanized 2–4 hours after drug injection. b) Blood, brain, and kidney rapamycin levels from cohorts treated with rapamycin or CCI-779 for four consecutive days and euthanized 24 hours after drug injection. c) Tumor rapamycin levels from indicated cohorts treated with rapamycin or CCI-779 and euthanized 2–4 hours after drug injection. Rapa = rapamycin. This data is shown in table format with statistical analyses in Table 2
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-0
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p>eived 8 mg/kg CCI-779 and 20,000 units IFN-γ by IP injection Monday through Friday for two months at the indicated ages. Severity of kidney disease was quantified both by counting the total number of cystadenomas and by scoring all the cystadenomas found. Average number of cystadenomas per kidney for indicated treatment cohort shown in bar graph (a) and table (c) format. Average cystadenoma score per kidney for indicated treatment cohort shown in bar graph (b) and table (d) format. Red error bars denote a statistically significant difference (P < 0.05) relative to untreated. "Both" in panels a-d refers to a combination of CCI-779 and IFN-γ. To illustrate the timing of kidney lesion genesis in untreated mice, graphs of average number of cystadenomas per kidney (e) and average cystadenoma score per kidney (f) are shown for cohorts of mice at different ages (3, 7 and 11 months; n = 6 mice for each age cohort). The asterisks in panels e and f indicate that the severity of kidney disease in untreated cohorts at 3 months and 11 months differs significantly from disease severity at 7 months (t-test, P ≤ 0.05)
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-7
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p>eived 8 mg/kg CCI-779 and 20,000 units IFN-γ by IP injection Monday through Friday for two months at the indicated ages. Severity of kidney disease was quantified both by counting the total number of cystadenomas and by scoring all the cystadenomas found. Average number of cystadenomas per kidney for indicated treatment cohort shown in bar graph (a) and table (c) format. Average cystadenoma score per kidney for indicated treatment cohort shown in bar graph (b) and table (d) format. Red error bars denote a statistically significant difference (P < 0.05) relative to untreated. "Both" in panels a-d refers to a combination of CCI-779 and IFN-γ. To illustrate the timing of kidney lesion genesis in untreated mice, graphs of average number of cystadenomas per kidney (e) and average cystadenoma score per kidney (f) are shown for cohorts of mice at different ages (3, 7 and 11 months; n = 6 mice for each age cohort). The asterisks in panels e and f indicate that the severity of kidney disease in untreated cohorts at 3 months and 11 months differs significantly from disease severity at 7 months (t-test, P ≤ 0.05)
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-3
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p>val in all treatment cohorts relative to untreated. c) Data shown in table format. P values listed are in comparison to the untreated cohort
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779-4
No full text<p><b>Copyright information:</b></p><p>Taken from "Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779"</p><p>http://www.biomedcentral.com/1471-2210/7/14</p><p>BMC Pharmacology 2007;7():14-14.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2213639.</p><p></p> the difference in growth pattern between the two treatment cohorts in the first 20 days of treatment. c) Survival curve for the early rapamycin and late rapamycin-treated cohorts. d) Data shown in table format
- …
